P. Bono

发表

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial

H. Joensuu, P. Kellokumpu-Lehtinen, K. Sunela, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.

P. Sharma, P. Ott, J. Rosenberg, 2016 .

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

A. Ravaud, R. Motzer, T. Choueiri, 2015, The New England journal of medicine.

Layilin, a novel integral membrane protein, is a hyaluronan receptor.

R. Hynes, P. Bono, J. Higgins, 2001, Molecular biology of the cell.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

S Michiels, C Desmedt, C Sotiriou, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Jorma Isola, Heikki Joensuu, Vesa Kataja, 2006, The New England journal of medicine.

A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC).

H. Wildiers, J. Jassem, L. Dirix, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.

K. Fizazi, C. Massard, P. Bono, 2017, European urology focus.

ODM-204 a novel dual inhibitor of CYP17A1 and androgen receptor: Early results from phase I dose escalation in men with castration-resistant prostate cancer.

K. Fizazi, C. Massard, P. Bono, 2017 .

Quantification of Plasma and Bone Marrow VEGF and Angiopoietin-2 Levels in Pediatric Malignancies

S. Andersson, P. Bono, S. Kivivuori, 2012, Journal of pediatric hematology/oncology.

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial

V. Kataja, A. Jukkola-Vuorinen, H. Joensuu, 2017, JAMA oncology.

S24 Update of the FINHER trial based on 5 years of follow-up

V. Kataja, J. Isola, H. Joensuu, 2009 .

Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo.

S. Jalkanen, M. Skurnik, M. Salmi, 2005, Immunity.

Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy

U. Hänninen, P. Bono, A. Lamminmäki, 2019, Acta oncologica.

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection

H. Isoniemi, T. Alanko, P. Bono, 2014, OncoTargets and therapy.

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial

V. Kataja, H. Joensuu, P. Kellokumpu-Lehtinen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib‐induced Hypertension in Metastatic Renal Cell Carcinoma

T. Poussa, P. Bono, K. Peltola, 2017, Clinical genitourinary cancer.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

H. Wildiers, J. Jassem, L. Dirix, 2015, Breast.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

J. Machiels, K. Miller, P. Karakiewicz, 2012, European journal of cancer.

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

H. Joensuu, P. Bono, T. Utriainen, 2011, Acta oncologica.

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma

C. Porta, M. Highley, E. Tartour, 2021, Cells.

Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

H. Joensuu, P. Bono, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy

H. Isoniemi, T. Poussa, T. Alanko, 2011, British Journal of Cancer.

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

H. Joensuu, T. Saarto, T. Alanko, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.

E. Jonasch, H. Kalofonos, N. Srihari, 2019, Clinical genitourinary cancer.

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.

T. Tammela, A. Snapir, K. Fizazi, 2016, European urology.

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

T. Ikonen, G. Curigliano, A. Italiano, 2020, ESMO Open.

Sunitinib‐induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma

H. Joensuu, F. Donskov, P. Bono, 2016, BJU international.

Comparing modular and personal service delivery in specialised outpatient care: A survey of haematology and oncology patient preferences

P. Torkki, A. Peltokorpi, M. Kaila, 2019, Health services management research.

Distinct ligand binding properties of Mac‐2‐binding protein and mousephilin C‐associated protein

S. Jalkanen, M. Salmi, P. Bono, 2001 .

Layilin, a cell surface hyaluronan receptor, interacts with merlin and radixin.

T. Jacks, R. Hynes, V. Ramesh, 2005, Experimental cell research.

Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.

T. Luukkaala, P. Kellokumpu-Lehtinen, K. Sunela, 2016, Clinical genitourinary cancer.

Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy.

V. Kosma, M. Karjalainen‐Lindsberg, E. Jantunen, 2010, European journal of cancer.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

P. Sharma, P. Ott, J. Rosenberg, 2016 .

Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma

H. Joensuu, P. Bono, T. Utriainen, 2014, Acta oncologica.

p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial

Aki Vehtari, C. Petropoulos, H. Joensuu, 2018, Clinical Cancer Research.

Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).

E. Jonasch, H. Kalofonos, N. Srihari, 2019, The oncologist.

Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial.

K. S. Hall, E. Wardelmann, H. Joensuu, 2015 .

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

C. Porta, A. Ravaud, R. Figlin, 2016, Clinical genitourinary cancer.

Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.

P. Ascierto, P. Sharma, P. Ott, 2016 .

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

M. Espié, Sung-Bae Kim, A. Schneeweiss, 2015, The Lancet. Oncology.

A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate.

F. D. De Braud, H. Joensuu, P. Casali, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors.

J. Chesnes, K. Alitalo, P. Heikkilä, 2008, Cancer cell.

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.

P. Ascierto, E. Lipson, F. Hodi, 2017 .

Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.

P. Sharma, P. Ott, M. Callahan, 2014 .

Origins of Serum Semicarbazide-Sensitive Amine Oxidase

K. Alitalo, S. Jalkanen, P. Bono, 2004, Circulation research.

VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.

K. Alitalo, P. Saharinen, P. Bono, 2011, Trends in molecular medicine.

High LYVE-1–Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer

P. Heikkilä, H. Joensuu, J. Lundin, 2004, Clinical Cancer Research.

Cloning of Vascular Adhesion Protein 1 Reveals a Novel Multifunctional Adhesion Molecule

S. Jalkanen, M. Salmi, P. Bono, 1998, The Journal of experimental medicine.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

G. Demetri, H. Joensuu, M. Heinrich, 2004 .

Cloning and characterization of mouse vascular adhesion protein-1 reveals a novel molecule with enzymatic activity.

S. Jalkanen, M. Salmi, P. Bono, 1998, Journal of immunology.

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer

C. Sotiriou, S. Loi, M. Piccart, 2013, Journal of the National Cancer Institute.

with Enzymatic Activity Adhesion Protein-1 Reveals a Novel Molecule Cloning and Characterization of Mouse Vascular

S. Jalkanen, M. Salmi, P. Bono, 2013 .

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial

P. Sharma, F. D. De Braud, P. Ott, 2016, The Lancet. Oncology.

Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma

H. Joensuu, A. Ristimäki, P. Saharinen, 2016, PloS one.

Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

M. Espié, Sung-Bae Kim, A. Schneeweiss, 2015 .

Helicobacter pylori and gastrointestinal symptoms in diagnostics and adjuvant chemotherapy of colorectal cancer

H. Rautelin, T. Poussa, P. Bono, 2013, Oncology letters.

Mammary-derived growth inhibitor (MDGI) interacts with integrin α-subunits and suppresses integrin activity and invasion

P. Heikkilä, H. Joensuu, J. Lundin, 2010, Oncogene.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Aki Vehtari, E. Wardelmann, H. Joensuu, 2012, JAMA.

Correlation of c‐Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib

H. Joensuu, A. Ristimäki, P. Bono, 2017, Clinical genitourinary cancer.

Elevated serum endostatin is associated with poor outcome in patients with non‐Hodgkin lymphoma

H. Joensuu, P. Bono, L. Teerenhovi, 2003, Cancer.

CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73

S. Jalkanen, L. Airas, M. Salmi, 1995, The Journal of experimental medicine.

Expression and prognostic value of transcription factor PROX1 in colorectal cancer

K. Alitalo, H. Joensuu, N. Linder, 2011, British Journal of Cancer.

The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck

L. Aaltonen, P. Vahteristo, A. Mäkitie, 2005, Journal of Medical Genetics.

Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients

S. Mustjoki, L. Paavolainen, Riku Turkki, 2021, Modern Pathology.

Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses

M. Ala-opas, A. Hemminki, K. Guse, 2007, Molecular Cancer Therapeutics.

CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).

P. Ascierto, P. Sharma, P. Ott, 2016 .

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.

T. Tammela, K. Fizazi, C. Massard, 2017, European urology focus.

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

T. Tammela, V. Kataja, N. James, 2014, The Lancet. Oncology.

ODM-201 and the CNS: A clinical perspective.

A. Snapir, T. Sarapohja, K. Fizazi, 2014 .

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

H. Joensuu, P. Casali, C. Spreafico, 2011, British Journal of Cancer.

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.

T. Tammela, V. Kataja, H. Joensuu, 2017, European urology focus.

Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer.

V. Kataja, H. Joensuu, N. James, 2022, Journal of Clinical Oncology.

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

R. Plummer, A. Snapir, I. Braña, 2020, British Journal of Cancer.

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.

V. Kataja, A. Jukkola-Vuorinen, H. Joensuu, 2009, The Lancet. Oncology.

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.

Jorma Isola, Heikki Joensuu, Vesa Kataja, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.

H. Joensuu, P. Virkkunen, P. Bono, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

P. Ascierto, B. Mellado, P. Sharma, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

E. Wardelmann, H. Joensuu, B. Nilsson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.

H. Joensuu, P. Casali, C. Spreafico, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial

S. Jalkanen, P. Jaakkola, T. Lönnberg, 2020, Clinical Cancer Research.

Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy

K. Taari, T. Mirtti, P. Bono, 2016, Scandinavian journal of urology.

Isolation, structural characterization, and chromosomal mapping of the mouse vascular adhesion protein-1 gene and promoter.

A. Palotie, S. Jalkanen, M. Salmi, 1998, Journal of immunology.

Isolation, structural characterization, and chromosomal mapping of the mouse vascular adhesion protein-1 gene and promoter.

A. Palotie, S. Jalkanen, M. Salmi, 1998, Journal of immunology.

The MDM 2 promoter polymorphism SNP 309 T R G and the risk of uterine leiomyosarcoma , colorectal cancer , and squamous cell carcinoma of the head and neck

L. Aaltonen, P. Vahteristo, A. Mäkitie, 2005 .

Prostate Cancer Safety and Antitumour Activity of ODM-201 ( BAY-1841788 ) in Castration-resistant , CYP 17 Inhibitor-naïve Prostate Cancer : Results from Extended Follow-up of the ARADES Trial

T. Tammela, V. Kataja, H. Joensuu, 2018 .

Prostate Cancer Safety and Antitumour Activity of ODM-201 ( BAY-1841788 ) in Chemotherapy-naïve and CYP 17 Inhibitor-naïve Patients : Follow-up from the ARADES and ARAFOR Trials

T. Tammela, K. Fizazi, C. Massard, 2018 .

Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.

V. Kataja, A. Jukkola-Vuorinen, H. Joensuu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

D. Schadendorf, P. Ascierto, R. Dummer, 2017 .

Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310.

C. Porta, D. Cella, U. de Giorgi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?

A. de Gramont, T. Poussa, P. Bono, 2014, European journal of cancer.

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

E. Wardelmann, H. Joensuu, M. Schlemmer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

J. Fletcher, G. Demetri, R. Herrmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

C. Porta, T. Powles, D. Cella, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

T. Powles, G. De Velasco, P. Kellokumpu-Lehtinen, 2019, European journal of cancer.

Very high quantitative tumor HER2 content and outcome in early breast cancer.

V. Kataja, J. Isola, H. Joensuu, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel Angiogenesis Markers as Long‐Term Prognostic Factors in Patients With Renal Cell Cancer

T. Luukkaala, P. Kellokumpu-Lehtinen, P. Saharinen, 2017, Clinical genitourinary cancer.

CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)

R. Motzer, E. Plimack, J. Sosman, 2015 .

VEGFR3 and CD31 as prognostic factors in renal cell cancer.

T. Luukkaala, P. Kellokumpu-Lehtinen, K. Sunela, 2015, Anticancer research.

Tumorigenesis and Neoplastic Progression An Extensive Tumor Array Analysis Supports Tumor Suppressive Role for Nucleophosmin in Breast Cancer

P. Heikkilä, H. Joensuu, M. Lundin, 2011 .

Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression.

H. Joensuu, A. Vaheri, I. Leivo, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

Michael Jeffers, Heikki Joensuu, Tim Eisen, 2012, The Lancet. Oncology.

Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC).

A. Jukkola-Vuorinen, H. Joensuu, P. Kellokumpu-Lehtinen, 2010 .

Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT

P. Bono, U. Saarinen-Pihkala, S. Kivivuori, 2013, Bone Marrow Transplantation.

3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

R. Motzer, E. Plimack, J. Sosman, 2015 .

Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer

A. Jukkola-Vuorinen, H. Joensuu, P. Kellokumpu-Lehtinen, 2010 .

Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)

V. Kataja, A. Jukkola-Vuorinen, H. Joensuu, 2013, Acta oncologica.

LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types

J. Koivunen, M. D. de Jonge, M. Karvonen, 2021, Annals of Oncology.

Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance

O. Kallioniemi, P. Heikkilä, H. Joensuu, 2009, Clinical Cancer Research.

VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer.

P. Heikkilä, K. V. von Smitten, P. Bono, 2007, American journal of clinical pathology.

Mouse vascular adhesion protein 1 is a sialoglycoprotein with enzymatic activity and is induced in diabetic insulitis.

S. Jalkanen, M. Salmi, P. Bono, 1999, The American journal of pathology.

Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.

H. Joensuu, C. Haglund, J. Lundin, 2005, Cancer research.

Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.

T. Tammela, K. Fizazi, C. Massard, 2015 .

A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).

T. Tammela, A. Snapir, K. Fizazi, 2014 .

Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.

T. Tammela, V. Kataja, H. Joensuu, 2014 .

862 Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials

K. Fizazi, C. Massard, P. Bono, 2014 .

Resection of Renal Cell Cancer Metastases: Where Do We Stand in 2008?

M. Ruutu, K. Taari, P. Bono, 2008 .

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Abstract PD10-06: CXCL13 mRNA predicts Docetaxel benefit in Triple Negative tumors

V. Kataja, J. Isola, M. Schmidt, 2012 .

Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.

V. Kataja, A. Jukkola-Vuorinen, H. Joensuu, 2016 .

674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032

D. Jäger, P. Ascierto, P. Sharma, 2017 .

CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).

R. Motzer, E. Plimack, J. Sosman, 2016 .

Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact

F. Donskov, P. Bono, K. Peltola, 2018, Acta oncologica.

C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients

P. Bono, K. Peltola, P. Penttilä, 2022, Acta oncologica.

Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.

D. Jäger, P. Sharma, P. Ott, 2018 .

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

E. Wardelmann, H. Joensuu, M. Schlemmer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma.

F. Donskov, P. Bono, K. Peltola, 2017, European journal of cancer.

Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40].

T. Powles, G. De Velasco, P. Kellokumpu-Lehtinen, 2019, European journal of cancer.

Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial.

C. Sotiriou, S. Loi, D. Larsimont, 2012 .

MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial

D. Jäger, P. Ascierto, P. Sharma, 2017 .

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial

P. Jaakkola, M. Karvonen, S. Iivanainen, 2023, medRxiv.

A mouse molecular mimic of human vascular adhesion protein-1.

S. Jalkanen, M. Salmi, P. Bono, 1997, Molecular immunology.

1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer

S. Jalkanen, P. Jaakkola, J. Koivunen, 2020 .

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma

H. Lähdesmäki, S. Mustjoki, T. Lönnberg, 2023, Journal of Clinical Investigation.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

A. Ravaud, R. Motzer, T. Choueiri, 2015, The New England journal of medicine.

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.

A. Ravaud, R. Motzer, M. Gore, 2013 .

Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)

C. Sotiriou, S. Loi, C. Desmedt, 2013 .

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

G. Demetri, H. Joensuu, M. Heinrich, 2004, Blood.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT.

C. Blank, V. Grünwald, P. Bono, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT.

C. Blank, V. Grünwald, P. Bono, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Cloning of Vascular Adhesion Protein 1 Reveals a Novel Multifunctional Adhesion Molecule

S. Jalkanen, M. Salmi, P. Bono, 1998, The Journal of experimental medicine.

Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer.

J. Isola, A. Mäkitie, T. Joensuu, 2010, Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale.

Modularising outpatient care delivery: A mixed methods case study at a Finnish University Hospital

P. Torkki, A. Peltokorpi, M. Kaila, 2018, Health services management research.

Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients.

H. Lähdesmäki, S. Mustjoki, T. Lönnberg, 2023, The Journal of clinical investigation.

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

H. Joensuu, P. Bono, T. Utriainen, 2011, Acta oncologica.